Carnot BioSciences, LLC
Carnot BioSciences, LLC is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Carnot BioSciences, LLC.
Carnot BioSciences, LLC is a company.
Key people at Carnot BioSciences, LLC.
Key people at Carnot BioSciences, LLC.
Carnot BioSciences, LLC is a biotechnology company specializing in protein engineering through directed evolution to develop novel protein-based therapeutics for rare metabolic diseases.[2][3][6] Formed as a spin-off from SmartZyme BioPharma in collaboration with HemoShear Therapeutics, it targets enzyme deficiencies and mutations causing metabolic disorders, such as propionic and methylmalonic acidemias, by modifying enzymes to better reduce toxins.[2][4] The company serves patients with rare genetic conditions lacking effective treatments, addressing unmet needs in enzyme replacement therapy amid a growing field of protein therapeutics.[2][4]
Headquartered in New York and founded in 2018, Carnot operated with a small team split between Boston and Israel, aiming to generate lead candidates by late 2019; its status is now listed as archived.[2][3]
Carnot BioSciences emerged in late 2018 as a joint venture spin-off from SmartZyme BioPharma, which divested its protein engineering platform to focus on diabetes-related glucose-sensing enzymes.[2][4][6] The partnership with HemoShear Therapeutics, a drug discovery firm targeting rare metabolic disorders, drove the creation; HemoShear identified promising enzyme targets, while Carnot applied directed evolution techniques to engineer improved versions.[2][4][7] Key figures include Brian Wamhoff, Ph.D., HemoShear co-founder and head of innovation, who highlighted the platform's potential for better patient outcomes.[2][4]
Early traction centered on undisclosed enzyme targets for inborn errors of metabolism, with a half-dozen scientists tasked with advancing programs toward clinical stages.[2] A related entity, Carnot Biosciences Co-development Corp., Inc., was filed in Albany, NY, on November 29, 2018.[5]
(Note: A trademark filing for "Carnot BioSciences" by Carnot Pharma, LLC suggests possible IP transitions, but details are limited.[8])
Carnot rode the 2010s boom in protein and enzyme therapeutics for rare metabolic disorders, where genetic mutations cause enzyme shortages leading to toxic buildups— a field gaining traction post-approvals like Kanuma in 2015.[2][4] Timing aligned with advances in directed evolution, enabling precise protein modifications amid rising demand for orphan drugs.[2][6] Market forces favoring it include regulatory incentives for rare diseases and HemoShear's human-relevant disease modeling, influencing the ecosystem by validating spin-off models for platform tech in biotech.[2][7] However, its archived status by recent records indicates challenges in sustaining momentum.[3]
Carnot's archived profile suggests it may have been acquired, wound down, or rebranded (potentially linking to Carnot Pharma's trademark), limiting visibility into ongoing programs.[3][8] Future prospects hinge on protein engineering's evolution, with trends like AI-accelerated directed evolution and expanded enzyme therapies for metabolic diseases potentially reviving similar platforms. Its influence could persist through licensed tech or team dispersal, underscoring spin-offs' role in biotech innovation—echoing its origin as a focused bet on unmet rare disease needs.[2][4]
